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ABSTRACT 
Aim of study: Drug-drug interaction (DDI) occurs when two or more drugs are simultaneously administered, where the effect of one 
drug is altered by the concomitant use of another drug. The prospective observational study aimed to assess the potential drug-drug 
interactions (pDDIs) in general medicine department of a multispecialty teaching hospital.  
Material & Methods: Data of all the patients admitted in the general medicine department was collected and analyzed for drug-drug 
interactions by using drug information resources such as “Thomson Reuters MICROMEDEX® 2.0 DRUGDEX and drugs.com.  
Results: A total of 150 case records were reviewed, 116 (77.33%) cases were identified with 273 potential drug- drug interactions 
during the study period.   It was observed that out of the 273 DDIs identified, majority 68.13% of the interactions were moderate in 
severity followed by 19.78% were minor and 12.08% were major. The categorization of onset of drug –drug interactions revealed 
that 53.47% were categorized as ‘not specified’ and the documentation status of drug – drug interactions showed that 56.77% were 
‘fair’ in nature.  
Conclusion: The study highlights the need of regular monitoring of drug therapy in identifying and preventing the medications that 
have the potential to cause drug-drug interactions thereby minimizing the undesirable outcomes in drug therapy and improving the 
quality of care. 
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INTRODUCTION 
A pharmaceutical drug is a chemical substance when 
introduced into the body produces an effect which is 
used to diagnose, cure, treat or prevent a disease or to 
promote well being. When a patient is suffering from 
multiple co-morbid conditions, concomitant use of many 
drugs is often necessary to achieve the goal of therapy. 
Multiple outcomes are likely to occur when patients use 
drugs and the possibility of encountering drug-drug 
interactions could rise in these cases. Drug-drug 
interactions (DDIs) in patients receiving multi-drug 
therapy are of wide concern. The term “drug-drug 
interaction” is used when the effect of one drug is 
changed or altered by the simultaneous use of another 
drug. The clinical productivity of such interactions 
could be antagonism, synergism or idiosyncratism
1
 
(Jimmy OD et al., 2012). 
There are large numbers of drugs available, due to 
which, the occurrence of DDI is high from the 
concomitant use of certain drug pairs. However, from 
physicians’ perspective, some DDIs are not clinically 
relevant and they believe that there is a requirement of 
concomitant use of the two drugs in order to achieve 
suitable therapeutic activity. In cases like these, to 
prevent the adverse effects that are associated with 
DDIs, careful monitoring of the laboratory and clinical 
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parameters of the patient is looked after. However, 
prescribing certain drugs together is contraindicated and 
clinically relevant DDIs could occur in case of 
concomitant use and may have adverse effects on the 
patient. Factors that favor the appearance of drug 
interactions are old age, polypharmacy, genetic factors, 
wrong choice of drug, wrong dosage, wrong route of 
administration, errors in taking the drug, failing to take 
account of hepatic and renal function
2
 (Nag KA et al., 
2011).. 
Potential drug-drug interactions (PDDIs) may include 
drug contraindications, combinations of drugs that 
require monitoring and possible dosage adjustments 
when given concomitantly or drugs which may be 
beneficial when administered collectively.
 
Consequence 
of drug interactions occur due to drug related problems 
which have a negative impact on morbidity, mortality, 
length of hospitalization, health care cost and quality of 
life. DDIs can result in anything, from minor 
morbidities up to fatal consequences. The main causes 
of hospital admission and mortalities are related to drug 
interactions and their corresponding adverse effects
3
 
(Kaliamurthy K et al., 2015). The risk of PDDIs 
increases by the increase in the number of drugs and in 
patients who are on long term therapy with multiple 
drugs and co-morbidities. Apt number of drugs for an 
individual varies greatly, depending on patient’s 
condition, functional status, life expectancy and 
preferences
4 
(Guthrie B et al., 2015). 
Drug interactions may occur by two or additional 
mechanisms acting together. The mechanisms of 
interaction can be distributed as pharmacokinetic and 
pharmacodynamic interactions. “Pharmacokinetic 
interactions” are those which can affect the processes by 
which drugs are absorbed, distributed, metabolized and 
excreted. “Pharmacodynamic interactions” are those in 
which the effects of one drug are transformed by the 
presence of another drug at its site of action
5 
(Pasqualetti 
G et al., 2015). 
In developed countries, patient safety has been 
improved by applying DDI software and by employing 
clinical pharmacists to detect and prevent DDIs. 
Physicians in developing countries still identify DDIs 
based on their own experiences
6
 (Baniasadi S et al., 
2015). Healthcare professionals evaluate the 
pharmacist’s response to drug interactions and recognize 
their knowledge of pharmacology and appreciate it. 
Hence, this study acts as an audit to assess the DDIs in 
the inpatients admitted in the general medicine 
department of a tertiary care teaching hospital and aims 
in reducing further occurrence of the same. 
MATERIALS AND METHODS 
Study design, site and duration 
A prospective observational study conducted for a 
period of eight months from November 2016 to June 
2017 in hospitalized patient under the general medicine 
department of a tertiary care teaching hospital centrally 
located in Dakshina Kannada, Mangaluru. The study 
was approved by Institutional Human Ethical 
Committee. 
Study criteria 
Inclusion criteria 
Patients of either gender, aged 18 years and above 
hospitalized in the general medicine wards, prescribed 
with two or more drugs. 
Exclusion criteria 
The patients receiving less than 24 hours in-patient care 
and patients who themselves have enrolled in any other 
investigational studies were excluded from the study. 
Data sources 
Patient case sheets including treatment charts and 
relevant laboratory investigations. 
Information received from patient caregivers. 
Materials used 
 Patient data collection form. 
 Micromedex- drug interaction checking software. 
 Stockley’s Drug Interactions Book. 
 Medscape multidrug interaction checker. 
 www.drugs.com. 
Study procedure 
All the hospitalized patients under the general medicine 
department were reviewed on daily basis from the day 
of admission till the day of discharge and those who met 
the study criteria were enrolled into the study. All the 
relevant and necessary details of the patients including 
the demographic data, laboratory parameters and drug 
therapy details were collected from the patient case 
notes and by interviewing patient bystanders and 
healthcare professionals if necessary.  The demographic 
details consists of age, gender, reason for admission, 
past medical history, medication history, co-morbities 
and any history of allergic reactions. The recording of 
laboratory parameters includes haematology, 
biochemistry and any other tests that were carried out 
during their hospital stay. The drug therapy details such 
as dose, duration, frequency, route, time of 
administration and concomitant drug were also noted. 
All the collected data were documented in the suitably 
designed data collection form designed as per the need 
of the study. The patient drug therapy were reviewed 
every day and assessed for any drug- drug interactions 
by using standard text books such as stockley’s drug 
interactions and online resources such as drug.com and 
micromedex software. The identified potential drug-
drug interactions were notified to the healthcare 
professionals for their appropriate action and were 
documented by the pharmacist in the drug –drug 
interaction documentation form. At the end of the study, 
the evaluation of potential drug-drug interactions was 
performed among the identified hospitalized patients for 
its level of severity, onset and documentation status of 
drug-drug interactions. 
Drug-drug interaction documentation form 
A suitable drug-drug interaction documentation form 
was designed by using various references so as to record 
the drug-drug interactions. These drug-drug interactions 
were categorized according to the level of severity 
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(mild, moderate and major), time of onset of potential 
(rapid, delayed and not-specified) and status of 
documentation (Excellent, Good, Fair, Poor and 
Unlikely). 
Data and statistical analysis:  
The data collected was compiled and entered into the 
Microsoft excel spread sheet and analyzed by using 
Statistical package of social sciences (SPSS) for 
windows (version 16.0). Continuous variable in the text 
and tables were expressed by mean ± SD and categorical 
data were presented as percentage and cumulative 
frequency. 
RESULTS 
General demographic characteristics of study 
population  
A total of 150 patient case records were reviewed in 
general medicine department during the eight months 
study period. Out of the 150 case records reviewed, 273 
potential drug-drug interactions were identified from 
116 patients in which 81(69.82%) patients were males 
and 35 (30.17%) patients were females. The mean age 
of the study population involved was found to be 53.22 
± 15.04 ranging from 18 to 83 years. Majority of the 
patients were in the age group of 41-60 years (43.96%) 
followed by age group of 61-80 years (31.03%). Among 
the co-morbidities, cardiovascular diseases (22.60%) 
was the most common co-morbidities identified among 
the study populations followed by endocrine disorders 
(17.95%), infectious diseases (15.17%), respiratory 
conditions (11.14%) and renal disorders (8.35%). Table 
2 shows the pattern of co-morbidities among the study 
populations. The demographic characteristics and the 
co-morbidities of the of the study subjects is shown in 
the following Table 1. 
 
Table 1: Demographic details of the study subjects 
Gender wise distribution  
Gender Frequency (n=116) Percentage  
Female 35 30.17 
Male 81 69.82 
Age wise categorization 
Age No of patients (n=116) Percentage  
0 – 20 5 4.31 
21 – 40 22 18.96 
41 – 60 51 43.96 
61 – 80 36 31.03 
≥ 81 2 1.72 
Co-morbities  
Disease Condition Frequency  Percentage  
Endocrine 58 17.95 
Infectious 49 15.17 
Cardiovascular 73 22.60 
Respiratory 36 11.14 
Renal 27 8.35 
Neurological 13 4.02 
Immune 2 0.61 
Hematological 16 4.95 
Bone 7 2.16 
Gastrointestinal 35 10.83 
Ophthalmology 4 1.23 
Dermatological 3 0.92 
 
Table 2: Pattern of medications prescribed in the study populations 
Category of drugs Frequency of drugs Percentage 
Cardiovascular agents 357 17.24 
Anti-infective agents 369 17.82 
Nutritional products 302 14.58 
Anti-diabetic agents 345 16.66 
Steroids 48 2.31 
Central nervous system agents 185 8.93 
Respiratory 201 9.71 
Gastro intestinal agents 263 12.70 
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System wise distribution of class of drugs prescribed 
among the study subjects 
The number of drugs prescribed to the patients in the 
study has been categorized according to the British 
national formulary system wise classification. As per the 
classification, most of the patients in our study 
population received drugs categorized under anti-
infective agents (17.82%) followed by cardiovascular 
drugs (17.24%) and anti-diabetic agents (16.66%). Table 
2 shows the overall pattern of medications that were 
prescribed in the study populations. 
Number of medications received by each patient of 
the study population 
Considering the number of drugs received by the 
patients, the average number of drugs received per 
patient was found to be 13.05 ± 5.764. Most of the 
patients (34.67%) in our study received 6 -10 drugs 
during their hospital stay. The number of medications 
received by the study population during their hospital 
stay is shown in the following figure 1. 
 
Distribution of cases with number of drug-drug 
interactions 
The number of potential DDI ranged from 1 to 10 in 
which 12 cases (10.34%) showed one potential DDI, 11 
cases (9.48%) showed two potential DDIs and 44 cases 
(37.93%) showed more than ten potential drug- drug 
interactions. The distribution of cases with number of 
drug-drug interactions is shown in the following table 3. 
 
Table 3: Distribution of cases with number of drug-
drug interactions 
No. of interactions 
per patient 
Frequency Percentage 
(%) 
1 12  10.34 
2 11  9.48 
3 8 6.89 
4 10  8.62 
5 9 7.75 
6 6 5.17 
7 7 6.03 
8 5  4.31 
9 4  3.44 
≥10 44 37.93 
 
Commonly involved drugs causing potential drug-
drug interactions 
Of the total 273 drug – drug interactions, the most 
common drugs involved in causing drug –drug 
interactions was found to be pantoprazole [54(19.78%)] 
followed by aspirin [36(13.18%)] and statins 
[34(12.45%)]. The involvement of other class of drugs 
in developing potential drug-drug interactions was 
shown in the following figure 2. 
 
Most prevalent potential DDIs among the study 
population 
The most commonly occurring interaction in the study 
was found to be between atorvastatin and pantoprazole 
(28) followed by budesonide and levalbuterol (18), 
aspirin + pantoprazole (17), pantoprazole with torsemide 
(15) and pantoprazole in combination with propranolol 
(14). The most prevalent potential drug-drug interactions 
among the study populations are shown in the table 4.
Table 4: Most prevalent drug-drug interactions in the study subjects 
Sl. No. Drug combination No. of cases Severity of DDIs 
1 Atorvastatin + Pantoprazole 28 Moderate 
2 Budesonide + Levalbuterol 18 Minor 
3 Aspirin + Pantoprazole 17 Minor 
4 Pantoprazole + Torsemide 15 Moderate 
5 Pantoprazole + Propranolol 14 Moderate 
6 Furosemide + Pantoprazole 12 Moderate 
7 Pantoprazole + Theophylline 12 Moderate 
8 Iron + Pantoprazole 11 Moderate 
9 Levalbuterol + Terbutaline 11 Moderate 
10 Budesonide + Terbutaline 11 Minor 
11 Clopidogrel + Pantoprazole 10 Moderate 
12 Azithromycin + Levalbuterol 10 Moderate 
13 Pantoprazole + Rifaximin 10 Moderate 
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Categorization of drug-drug interactions according 
to the level of severity, based on their onset and 
according to their documentation status. 
According to severity level classification of drug-drug 
interactions, 68.13% were moderate in severity, 19.78% 
were minor interactions and 12.08% were major 
interactions found. Based upon the onset of drug-drug 
interactions, it was found that majority of the 
interactions’ (53.47%) onset was not specified and the 
delayed onset of interaction was found to be 30.03% and 
rapid onset were seen in 16.48% of interactions. Of the 
total 273 potential drug-drug interactions identified in 
the study, 8.42% were documented as excellent 
followed by 34.79% were good and 56.77% were fair in 
nature. The study could not identify any drug-drug 
interactions that have been documented under the 
category poorly and unlikely. The classification of drug-
drug interactions according to their level of severity, 
based on their onset and according to their 
documentation status is shown in the following Table 5. 
 
Table 5: types of drug-drug interactions 
Types of drug interactions Total number of drug 
interactions (n=273) 
Percentage  
Classification based on severity 
Major  33 12.08 
Moderate  186 68.13 
Minor                            54 19.78 
Classification based on Onset  
Delayed  82 30.03 
Rapid  45 16.48 
Not specified   146 53.47 
Classification based on their documentation status 
Fair  155 56.77 
Good  95 34.79 
Excellent  23 8.42 
 
DISCUSSION 
Drug-drug interactions (DDIs) are a concern for all stake 
holders, especially patients and this risk increases as 
greater number of medications was commonly used to 
manage complex conditions. The present study revealed 
that the overall prevalence of potential drug-drug 
interactions were 77.33% which comparable to the other 
studies which encountered potential drug-drug 
interactions ranging from 45% - 78% 
7,8,9
 ( Ismail M et 
al 2011; Cruciol-Souza JM et al 2006; Lubinga SJ et al 
2011). A male predominance in patients with drug 
related problems were seen when compared to female 
populations. It indicates that male patients might have 
received more co-prescription of multiple medications 
for several physical and chronic health conditions. At 
present the available results in the literature regarding 
the role of gender are incongruous and the increase in 
frequency of drug –drug interactions in males10,11 
(Umretiya T. et.al., 2015; Bhagavathula A.S. et al., 
2014) are not found by all researchers
12,13
 (Patel P.S. et 
al., 2014; Teixeira J.J.V et al., 2012).  
The mean age in the present study was 53.22 ± 15.04. 
Majority (44%) of the patients in this study belonged to 
age group 41-60 years and also, the potential drug-drug 
interactions were widely seen in patients of the same age 
group. A study showed similar results
14
 (Ahmad A et al., 
2015) but is in contrast with another study in which 
majority was seen in lower age group
15
 (Vonbach P et 
al., 2008). The reason behind this may probably be 
because their study was a cross sectional study 
conducted in an underdeveloped country. But the present 
study was conducted in hospitalized patients in the 
general medicine ward in south India where elderly 
individuals were exposed to more multiple regimens 
than younger individuals, which increase the risk of 
pDDIs. 
The average medications prescribed per patient, in the 
study population was 13.05 ± 5.764. the incidence of 
potential drug-drug interactions is close to 40% in 
patients taking 5 drugs and exceeds 80% in patients 
taking more than seven medications. This result was 
contrary to a study carried out in outpatient general 
medicine department of a tertiary care teaching 
hospital
16
 (Baxter K et. al., 2014). This discrepancy 
could have occurred because of the different designs of 
the studies. Our study carried out in hospitalized patients 
where the likelihood of causing potential drug-drug 
interactions are very high because of sever and multiple 
illness, co-morbid conditions, chronic therapeutic 
regimen, multiple medications and frequent changes in 
drug therapy. 
Cardiovascular disorders were the most common clinical 
condition observed in this study. This is because; the 
patients involved in the study had more cardiovascular 
co-morbidities either on admission, or as past medical 
history. Also, the recent studies show that India faces a 
burden of cardiovascular diseases as the highest 
occurring disease. The study results showed the same 
clinical condition in majority of the admitted patients
 
in 
some of the studies
17, 18
 (Soherwardi S et al., 2015) 
(Dominic A et.al., 2015). 
While categorizing the number of drugs received by the 
study subjects, it was observed that anti-infective agents 
were the most commonly prescribed ones in general 
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medicine department, followed by cardiovascular agents. 
Since, in the study, cardiovascular disease followed by 
endocrine, infectious and respiratory is more observed, 
more number of antimicrobials agents are prescribed and 
given as treatment and prophylaxis for these diseases. 
Hence, more number of anti-infective agents are 
prescribed overall. Cardiovascular diseases being 
majority in occurrence, makes it a possible reason for 
cardiovascular agents to be prescribed
19
 (Kumaraswamy 
RC et al., 2014).  
More than 10 interactions were seen in majority (38%) 
of the study population conducted in this study whereas 
majority of patients had one interaction in a previous 
study
20
 (Sharma S. et al., 2014).
 
This discrepancy could 
have occurred because of the difference in selection of 
the patients. Sharma and co-workers carried out the 
study in patients with cardiovascular diseases where as 
our study included all the patients irrespective of their 
diagnosis. 
The most frequently occurring interaction identified in 
our study was between atorvastatin and pantoprazole. As 
majority of the patients were suffering from 
cardiovascular disease, statins were prescribed for the 
treatment of arthrosclerosis and also as prophylaxis for 
the secondary prevention of cardiovascular diseases. 
When the patients were prescribed with multiple 
medications, there is a possibility that it might lead to 
occurrence of drug induced gastritis leading to co-
prescribing of proton pump inhibitors. Also studies 
carried out by various authors in different setting 
showed that Ceftriaxone + Furosemide and 
Acetaminophen + Pantoprazole were the most common 
pairs of drug-drug interactions identified in their 
study
21,22
 (Sweileh WM et al., 2014) (Guo J J et al., 
2015). This difference between the present study and 
other studies may possibly be due to diverse factors 
including high utilization of medications which have 
more potential for interaction, different study designs 
and difference in software used. 
The most noticeable drug involved in causing pDDIs in 
this study is pantoprazole But few other studies that have 
carried out previously has shown that  ciprofloxacin and 
ACE inhibitors are responsible for more number of 
drug-drug inetractions
23,24
 (Nabovati E et al., 2016) 
(Nikolic B et al., 2014). The results of this study also 
highlight this area as most of the DDIs were identified in 
such prescriptions. Awareness program must be raised 
by stakeholders to educate health professionals 
regarding the rational use of drugs in these conditions. 
According to severity, this study showed majority 
(68.13%) of interactions as moderate followed by minor 
and then major in severity. These results are in line with 
the other studies which also showed that majority of the 
drug-drug interactions were ‘moderate’ in level of 
severity
25
 (Van Leeuwen RWF et al., 2013). Interactions 
being moderate in severity explain a condition wherein, 
exacerbation of the patient’s condition is seen. Such 
conditions may require an alteration in therapy. 
According to onset of pDDIs, majority (53.47%) of 
interactions in our study belongs to the category ‘not 
specified’. These findings were comparable with the 
results obtained that have reported previously 
26
 (Doan J 
et. al., 2013). This indicates that the interactions will not 
be evident immediately on administration of drugs, but 
when these drugs are continued, it would result in 
adverse effects. In cases like these, patients have to be 
closely and carefully monitored by the physician and the 
nursing staff. 
The documentation of 155 identified drug –drug 
interactions were fair (56.77%), 95 (34.79%) were good 
and 23 (8.82%) were excellent in nature. Similar results 
were seen in a study conducted previously
27
 (Tavakoli- 
Ardakani M et al.,
 
2013). Fair documentation status 
reveals a state where poor documentation is available 
but pharmacological considerations may perhaps lead 
clinicians to suspect the existence of a drug interaction. 
CONCLUSION 
The present study shows a high prevalence of potential 
drug-drug interactions in hospitalized patients of general 
medicine wards of tertiary care hospital. The use of 
electronic database systems as decision support tools, 
automated prescription alerts to doctors, conducting 
educational programs and vigilant towards drug 
selection can decrease the negative outcomes of pDDIs. 
So a regular review of the drug therapy by a clinical 
pharmacist in a multidisciplinary team may helps to 
identify and prevent potential drug-drug interactions 
especially in patients with chronic disease receiving 
multiple associated with their co-morbid conditions. 
These will in turn help to optimize drug therapy, 
improve the quality of care and condense the undesirable 
outcomes in the patient drug therapy.  
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